These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17695515)

  • 1. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model.
    Higgins B; Kolinsky K; Linn M; Adames V; Zhang YE; Moisa C; Dugan U; Heimbrook D; Packman K
    Anticancer Res; 2007; 27(4B):2279-87. PubMed ID: 17695515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
    Kolinsky K; Zhang YE; Dugan U; Heimbrook D; Packman K; Higgins B
    Anticancer Res; 2009 Jan; 29(1):91-8. PubMed ID: 19331137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models.
    Fujimoto-Ouchi K; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):211-6. PubMed ID: 11935213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
    Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
    Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
    Gajria D; Feigin K; Tan LK; Patil S; Geneus S; Theodoulou M; Norton L; Hudis CA; Traina TA
    Cancer; 2011 Sep; 117(18):4125-31. PubMed ID: 21387266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
    Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
    Miller KD; Chap LI; Holmes FA; Cobleigh MA; Marcom PK; Fehrenbacher L; Dickler M; Overmoyer BA; Reimann JD; Sing AP; Langmuir V; Rugo HS
    J Clin Oncol; 2005 Feb; 23(4):792-9. PubMed ID: 15681523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
    Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
    Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
    Osako T; Ito Y; Takahashi S; Tokudome N; Iwase T; Hatake K
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):159-64. PubMed ID: 17882419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
    Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
    Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding study of capecitabine in combination with weekly paclitaxel for patients with anthracycline-pretreated metastatic breast cancer.
    Susnjar S; Bosnjak S; Radulovic S; Stevanovic J; Gajic-Dobrosavljevic M; Kreacic M
    J BUON; 2007; 12(2):189-96. PubMed ID: 17600871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
    Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ;
    Oncology; 2004; 67(2):117-22. PubMed ID: 15539915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
    Miles D; Zielinski C; Martin M; Vrdoljak E; Robert N
    Eur J Cancer; 2012 Mar; 48(4):482-91. PubMed ID: 22257791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.